Deniece Riviere

Ms. Deniece Riviere

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
GLGeke Litjens
Geke Litjens
DRDeniece Riviere
Deniece Riviere
EGErwin Geenen
Erwin Geenen
SRS. A. Radema
S. A. Radema
LBLodewijk A. A. Brosens
Lodewijk A. A. Brosens
JHJohn J . Hermans
John J . Hermans
Background: At the time of surgery, approximately 10–20% of the patients with pancreatic cancer are considered unresectable because of unexpected liver metastasis, peritoneal carcinomatosis or locally advanced disease. This leads to futile surgical treatment with all the associated morbidity, mortality and costs. More than 50% of all liver metastases develop in the first six months postoperatively. These (subcentimeter) liver metastases are most likely already present at the time of diagnosis and have not been identified pre-operatively, due to the poor sensitivity of routine preoperative contrast-enhanced CT (CECT). Methods: The DIA-PANC study is a prospective, international, multicenter, diagnostic cohort study investigating diffusion-weighted, contrast-enhanced MRI for the detection of liver metastases in patients with all stages of pancreatic cancer. Indeterminate or malignant liver lesions on MRI will be further investigated histopathologically. For patients with suspected liver lesions without histopathological proof, follow up imaging with paired CT and MRI at 3-, 6- and 12-months will serve as an alternative reference standard. Discussion: The DIA-PANC trial is expected to report high-level evidence of the diagnostic accuracy of MRI for the detection of liver metastases, resulting in significant value for clinical decision making, guideline development and improved stratification for treatment strategies and future trials. Furthermore, DIA-PANC will contribute to our knowledge of liver metastases regarding incidence, imaging characteristics, their number and extent, and their change in time with or without treatment. It will enhance the worldwide implementation of MRI and consequently improve personalized treatment of patients with suspected pancreatic ductal adenocarcinoma. Trial registration: ClinicalTrials.gov Identifier: NCT03469726. Registered on March 19th 2018 - Retrospectively registered.

26 July 2024 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
DRDeniece Riviere
Deniece Riviere
PBPeter B van Den Boezem
Peter B van Den Boezem
MBMarc G Besselink
Marc G Besselink
CLCornelis Jhm van Laarhoven
Cornelis Jhm van Laarhoven
DKDavid A Kooby
David A Kooby
KGKurinchi Selvan Gurusamy
Kurinchi Selvan Gurusamy

25 November 2023 in HPB
Verified
Journal Article
Open access
DRDeniece Riviere
Deniece Riviere
EAErik Aarntzen
Erik Aarntzen
EGErwin van Geenen
Erwin van Geenen
DCDavid Chang
David Chang
Lioe-Fee de Geus-OeiLioe-Fee de Geus-Oei
Lioe-Fee de Geus-Oei
JHJohn J . Hermans
John J . Hermans
Retrospective analysis to investigate the relationship between the flow-metabolic phenotype and overall survival (OS) of pancreatic ductal adenocarcinoma (PDAC) and its potential clinical utility. Patients with histopathologically proven PDAC between 2005 and 2014 using tumor attenuation on routine pre-operative CECT as a surrogate for the vascularity and [18F]FDG-uptake as a surrogate for metabolic activity on [18F]FDG-PET. In total, 93 patients (50 male, 43 female, median age 63) were included. Hypoattenuating PDAC with high [18F]FDG-uptake has the poorest prognosis (median OS 7 ± 1 months), compared to hypoattenuating PDAC with low [18F]FDG-uptake (median OS 11 ± 3 months; p = 0.176), iso- or hyperattenuating PDAC with high [18F]FDG-uptake (median OS 15 ± 5 months; p = 0.004) and iso- or hyperattenuating PDAC with low [18F]FDG-uptake (median OS 23 ± 4 months; p = 0.035). In multivariate analysis, surgery combined with tumor differentiation, tumor stage, systemic therapy and flow metabolic phenotype remained independent predictors for overall survival. The novel qualitative flow-metabolic phenotype of PDAC using a combination of CECT and [18F]FDG-PET features, predicted significantly worse survival for hypoattenuating-high uptake pancreatic cancers compared to the other phenotypes.

7 March 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
DRDeniece Riviere
Deniece Riviere
MMMarnix C. Maas
Marnix C. Maas
LBLodewijk A. A. Brosens
Lodewijk A. A. Brosens
MSMartijn W. J. Stommel
Martijn W. J. Stommel
KLKees van Laarhoven
Kees van Laarhoven
JHJohn J . Hermans
John J . Hermans
This study evaluated the relationship between apparent diffusion coefficient (ADC) values in pancreatic ductal adenocarcinoma (PDAC) and tumor grades based on WHO, Adsay, and Kalimuthu classifications, using whole-mount pancreatectomy specimens. If glandular formation plays a key role in the degree of diffusion restriction, diffusion-weighted imaging could facilitate non-invasive grading of PDAC. A freehand region of interest (ROI) was drawn along tumor borders on the preoperative ADC map in each tumor-containing slice. Resection specimens were retrospectively graded according to WHO, Adsay, and Kalimuthu classifications and correlated with overall survival and the 10th percentile of whole-volume ADC values. Findings from 40 patients (23 male, median age 67) showed no correlation between ADC p10 values and WHO differentiation (p = 0.050), Adsay grade (p = 0.955), or Kalimuthu patterns (p = 0.117). There was no association between ADC p10 and overall survival (p = 0.082) and other clinicopathological variables. Survival was significantly lower for poor tumor differentiation (p = 0.046) and non-glandular Kalimuthu patterns (p = 0.016) and there was a trend towards inferior survival for Adsay G3 (p = 0.090) after correction for age, tumor location, and stage. Preoperative ADC measurements for determining PDAC aggressiveness had limited clinical utility, as there was no correlation with histological parameters or overall survival in resectable PDAC.